Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTXM83 plus CHOP versus rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma
ISRCTN26918647Phase 3Completed
- Sponsor
- mAbxience
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by mAbxience. Primary endpoint: Response rate. Started Nov 2012; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN26918647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26918647.